Hyperactivation of Cdk5 during diseased conditions results in upregulation of major disease hallmarks, i.e., Aβ-amyloid, Tau, and pTau, and downregulation of Mcl1, as observed in the AD cellular model. This evidence concerns the gene MAPT and Alzheimer disease.